Gyre Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Gyre Therapeutics, Inc. (GYRE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 0 shares for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-10-26.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2023-10-26
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-09-30 was 0.00 shares.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-06-30 was 0.00 shares.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-03-31 was 0.00 shares.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2015-06-30 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month |
|---|---|---|---|---|
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | 0.00 shares derived: sum of 2 quarters · filed 2023-10-26 | 0.00 shares 10-Q · filed 2023-10-26 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 0.00 shares 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-15 | |||
| 2015-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | 111.03K shares 10-Q · filed 2015-07-31 | ||
| 2015-03-31 | 111.03K shares 10-Q · filed 2015-05-07 | |||
| 2014-09-30 | 6.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | 6.75K shares derived: sum of 2 quarters · filed 2014-11-06 | 849.12K shares 10-Q · filed 2014-11-06 | |
| 2014-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | 842.37K shares 10-Q · filed 2014-08-07 | ||
| 2014-03-31 | 842.37K shares 10-Q · filed 2014-05-08 | |||
| 2013-09-30 | 102.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | 845.15K shares 10-Q · filed 2013-11-06 | ||
| 2013-06-30 | 743.05K shares 10-Q · filed 2013-08-07 | |||
| 2013-01-17 | 573.05K shares 10-Q · filed 2013-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |